Supplementary information

Evaluation of isotype specific salivary antibody assays for detecting previous SARS-CoV-2 infection in children and adults

Amy C Thomas^{1,2*}, Elizabeth Oliver³, Holly E Baum³, Kapil Gupta^{4,5,6}, Kathryn L Shelley^{4,5,7}, Anna E Long⁸, Hayley E Jones¹, Joyce Smith³, Benjamin Hitchings³, Natalie di Bartolo^{4,9}, Vasileiou⁴, Fruzsina Rabi⁴, Hanin Alamir³, Malak Eghleilib³, Ore Francis², Kate Jennifer Oliver¹⁰, Begonia Morales-Aza³, Ulrike Obst¹¹, Debbie Shattock¹², Rachael Barr^{3,13}, Collingwood¹⁰, Kaltun Duale³, Niall Grace¹⁰, Lucy Guillaume Gonnage Livera¹⁰, Harriet Fernanda Rodrigues¹⁵, Nicholas Timpson^{1,16}, Bishop¹⁰, Downing¹⁴, Lindsay Caroline L Relton¹⁶, Ashley Toye^{4,9}, Derek N Woolfson^{4,5,7}, Imre Berger¹⁷, Anu Goenka³, Andrew D Davidson¹¹, Kathleen M Gillespie⁸, Alistair JK Williams⁸, Mick Bailey², Ellen Brooks-Pollock¹, Adam Finn^{1,3,18†}, Alice Halliday^{3†} & the CoMMinS Study Team

* Corresponding author: amyc.thomas@bristol.ac.uk

[†]Contributed equally

¹School of Population Health Sciences, Bristol Medical School, University of Bristol, UK. ²Bristol Veterinary School, University of Bristol, UK. ³Bristol Vaccine Centre, School of Cellular and Molecular Medicine, University of Bristol, UK. ⁴School of Biochemistry, University of Bristol, Bristol, UK. ⁵BrisSynBio, University of Bristol, Bristol, UK. ⁶Imophoron Ltd, Science Creates, Old Market, Midland Road, Bristol, UK.⁷School of Chemistry, University of Bristol, Bristol, UK. ⁸Translational Health Sciences, Bristol Medical School, University of Bristol, UK.⁹NIHR Blood and Transplant Research Unit in Red Cell Products, University of Bristol, UK. ¹⁰Bristol Vaccine Centre, School of Population Health Sciences, University of Bristol, UK. ¹¹School of Cellular and Molecular Medicine, University of Bristol, UK. ¹²Bristol Bioresource Laboratories, Population Health Sciences, Bristol Medical School, University of Bristol, UK.¹³Bristol Royal Hospital for Children, University Hospitals Bristol and Weston NHS Foundation Trust, Upper Maudlin Street, Bristol, BS2 8BJ. ¹⁴NIHR Bristol Biomedical Research Centre, University of Bristol, UK. ¹⁵Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, Portugal. Faculdade de Medicina, Universidade de Coimbra. ¹⁶MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, Bristol, UK. ¹⁷Max Planck Bristol Centre for Minimal Biology, University of Bristol, Bristol, UK. ¹⁸Paediatric Immunology & Infectious Diseases, Bristol Royal Hospital for Children, Bristol, UK.




Figure S1: Optimisation of SARS-CoV-2 salivary ELISA conditions. a, Comparison of binding to high and medium binding plates based on reactivity to spike IgA. Negative sample: no previous SARS-CoV-2 exposure history or symptoms; positive sample from a clinically suspected donor (laboratory unconfirmed infection) **b.** Optimisation of antigen coating concentration based on responses to N-protein, RBD and Spike IgA. Blue data points show data from negative samples (healthy donor with no previous SARS-CoV-2 exposure history or symptoms); yellow data points show data from positive samples (N-protein: convalescent PCR-confirmed COVID-19 pool from 3 donors; RBD and spike: one clinically suspected COVID-19 donor); grey data points show data from serum standard (convalescent PCR-confirmed COVID-19 pool from 3 donors). c, Optimisation of secondary antibody (IgA and IgG) concentration and sample dilution using checkerboard titrations. Blue data points show data from negative samples (healthy donor with no previous SARS-CoV-2 exposure history or symptoms), yellow data points show data from positive samples (N-protein: convalescent PCR confirmed COVID-19 pool from 3 donors; RBD and spike IgA: one clinically suspected COVID-19 sample; RBD and spike IgG: convalescent PCR confirmed COVID-19 donor). Different shapes show data from each of the secondary antibody concentrations tested, ranging from 1 in 5,000 to 1 in 30,000. d, Representative serial dilution curves showing isotype specific (IgA and IgG) salivary responses to spike, RBD and N-protein. Blue data points show data from negative (pre-pandemic) samples, yellow data points show data from positive (convalescent PCR confirmed) samples.




Figure S2: Impact of heat inactivation and freeze-thawing on isotype specific reactivity to spike protein. a, c, Reactivity to spike IgA. b, d, Reactivity to spike IgG. Blue triangle data points show data from negative samples (pre-pandemic), yellow circle and square data points show data from positive samples (convalescent PCR confirmed COVID-19 = circle; one clinically suspected COVID-19 sample = square. Solid bar is the mean of each negative and positive group at each condition. OD = optical density (absorbance at 450 nm and background at 570 nm). Experiments were performed once.




Figure S3: Dotplots and ROC curves for threshold set samples. a-f, Dotplots show the scatter of values. Data are presented for known negative and known positive samples tested in the threshold set, the number of samples tested in each group is shown under the corresponding data points. Proposed thresholds (97th – 99th percentile and Youden's index) are shown as dashed lines. For N-protein and Spike, final thresholds are shown as dashed blue lines. **g-i**, ROC curves represent assay performance using the samples true known negative and positive status. ROC = receiver operating characteristic. AUC = area under the ROC curve. Norm OD = Normalised OD (a relative ratio to the serum standard). N-protein = Nucleocapsid protein. RBD = Receptor binding domain.




Figure S4: Dot plots and ROC curves for validation set samples. a-d, Dotplots show the scatter of values. Data are presented for known negative and known positive samples tested in the validation set, the number of samples tested in each group is shown under the corresponding data points. For N-protein and Spike, final thresholds are shown as dashed blue lines; e, f, ROC curves represent assay performance. ROC = receiver operating characteristic. AUC = area under the ROC curve. Norm OD = Normalised OD (a relative ratio to the serum standard). N-protein = Nucleocapsid protein. RBD = Receptor binding domain.




Figure S5: Specificity and sensitivity comparison using different threshold methods. Thresholds were applied to validation sample set only and threshold and validation sets combined. The threshold method is represented by colour and sample set by line type.




Figure S6: SARS-CoV-2 specific IgA and IgG responses among samples collected from different prepandemic cohorts. Responses stratified by age (adult vs child), represented by colour: pink = children and blue = adults. Results expressed as normalised optical density (OD); a relative ratio to the serum standard. N-protein = nucleocapsid protein; RBD = receptor binding domain. Antibody responses were compared across multiple groups using the Kruskal-Wallis test with post-hoc testing using Dunn's test. Significant Bonferroni corrected pair-wise comparisons are shown ($p \le 0.05$).




Figure S7: Positive and negative predictive values for N-protein IgA and IgG and Spike IgA and IgG assays over 4 different thresholds. These are implied values of PPV (positive predictive value) and NPV (negative predictive value) based on Table 2 sensitivity and specificity estimates. NPVs are shown in pink and PPVs are shown in blue. Each of the different threshold methods are shown with a different shape: 97^{th} percentile = circle; 98^{th} percentile = triangle; 99^{th} percentile = square; Youden's index = cross.




Figure S8: Dynamics of salivary and serum spike antibody responses. a-d, Distribution of salivary and serum spike IgA and IgG antibody in relation to time since symptom onset and age. Salivary samples positive for either spike IgA (n=28) or spike IgG (n=40) according to validated thresholds (shown as grey dotted lines) and corresponding paired serum samples are shown. **e**, Relationship between age of participant and days post symptom onset. Each point is an individual, lines and shaded areas are representative of the smoothed mean (loess method) and corresponding 95% confidence interval. Grey dashed horizontal line indicates the thresholds for salivary spike IgA and IgG positivity. NormOD = normalised OD (relative ratio to a pooled serum standard).




Figure S9: Shedding profiles for PCR-confirmed index cases (n=19) and PCR-confirmed contacts (n=17) during the household study. Saliva samples were tested by RT-qPCR for SARS-CoV-2 infection. The threshold for positivity was 35 cycles, shown as the horizontal blue dashed line. Contacts and index cases are shown in yellow and green respectively. Shape denotes PCR result: negative = circle; positive = triangle.




Figure S10: Dynamics of salivary N-protein and spike IgA and IgG responses in children and adults in household outbreaks. Responses stratified by COVID-19 vaccination, infection status based on RT-qPCR performed on the same saliva sample tested for antibodies and participant (adult/child status). Top two panels show antibody responses for uninfected individuals by vaccination status. Bottom two panels show antibody responses infected individuals by vaccination status. Bottom two panels show antibody responses infected individuals by vaccination status. Samples from adults are represented with a circle, samples from children (<18 years) are represented with a triangle. Four individuals with infection ≥ 10 days prior to Day 0 are shown in blue. Thresholds for antibody positivity are indicated with a blue dashed horizontal line. Norm OD = Normalised OD (a relative ratio to the serum standard). N-protein = Nucleocapsid protein.

Table S1: Evaluation of threshold methods. Using samples in the threshold set, performance over four thresholds was evaluated. AUC = Area under the curve. 95% CI = 95% confidence interval; calculated for AUC using DeLong's method or computed with 10,000 stratified bootstrap replicates for sensitivity and specificity estimates.

				Threshol	d sample set	
Assay	n pre-pandemic	n PCR-confirmed		UC	95%	
Spike IgA	109	42		2.2	88.1-	
Spike IgG	98	41	94	4.9	91.6-	98.3
N-protein IgA	78	38	71.2		62.0-	80.5
N-protein IgG	78	37	7′	7.3	68.7-	85.9
RBD IgA	62	34	74	4.7	64.8-	84.6
RBD IgG	61	32	70	0.6	60.0-	81.2
	Threshold method	Threshold value (Normalised OD)	Specificity	95% CI	Sensitivity	95% CI
Spike IgA	99th percentile	0.384	98.2	95.4-100	40.5	26.2-54.8
	98th percentile	0.368	97.2	93.6-100	42.9	28.6-57.1
	97th percentile	0.317	96.3	92.7-99.1	54.8	40.5-69
	Youden's index	0.178	85.3	78.9-91.7	85.7	73.8-95.2
Spike IgG	99th percentile	0.339	98	94.9-100	48.8	34.1-63.4
	98th percentile	0.306	96.9	92.9-100	53.7	39-68.3
	97th percentile	0.272	95.9	91.8-99	58.5	43.9-73.2
	Youden's index	0.093	84.7	77.6-91.8	97.6	92.7-100
N-protein IgA	99th percentile	0.799	98.7	96.2-100	2.63	0-7.89
	98th percentile	0.592	97.4	93.6-100	5.26	0-13.2
	97th percentile	0.524	96.2	91-100	7.89	0-18.4
	Youden's index	0.112	51.3	39.7-61.5	92.1	84.2-100
N-protein IgG	99th percentile	0.588	98.7	96.2-100	5.41	0-13.5
	98th percentile	0.484	97.4	93.6-100	8.11	0-18.9
	97th percentile	0.420	96.2	91-100	8.11	0-18.9
	Youden's index	0.095	74.4	64.1-83.3	70.3	56.7-83.8
RBD IgA	99th percentile	1.50	98.4	95.2-100	0	0-0
	98th percentile	1.41	96.8	91.9-100	0	0-0
	97th percentile	1.31	96.8	91.9-100	0	0-0
	Youden's index	0.371	67.7	56.5-79	79.4	64.7-91.2
RBD IgG	99th percentile	0.611	98.4	95.1-100	18.2	6.1-30.3
	98th percentile	0.604	96.7	91.8-100	18.2	6.1-30.3
	97th percentile	0.583	96.7	91.8-100	18.2	6.1-30.3
	Youden's index	0.138	57.4	44.3	81.8	66.7-93.9

Assay	Sample ID*	Mean/SD/ %CV	Plate 1	Plate 2	Plate 3	Plate 4	Plate 5	Plate 6	Plate 7	Plate 8	Plate 9	Plate 10	Inter-assay mean	Inter- assay SD	Inter-assay %CV
	Saliva	Mean (norm.)	0.11	0.13	0.09	0.12	0.11	0.10	0.10	0.16	0.11	0.14			
	Neg	SD	0.02	0.02	0.01	0.01	0.02	0.01	0.02	0.02	0.01	0.00	0.12	0.02	18.93
N-protein	QC	%CV	10.88	10.02	6.77	5.60	8.20	4.70	10.20	9.10	4.20	2.00			
IgA	Pooled	Mean (OD)	1.48	1.49	1.43	2.30	2.20	2.21	2.18	1.43	1.34	1.49			
	+	SD	0.01	0.00	0.03	0.05	0.04	0.02	0.05	0.03	0.04	0.01	1.75	0.41	23.10
	serum	%CV	0.57	0.33	2.02	2.20	1.80	0.80	2.30	2.30	2.70	0.70			
	Saliva	Mean (norm.)	0.09	0.09	0.11	0.11	0.14	0.14	0.13	0.13	0.15	0.15			
	Neg	SD	0.02	0.01	0.01	0.00	0.00	0.02	0.01	0.01	0.05	0.01	0.12	0.02	19.28
N-protein	QC	%CV	7.54	3.86	5.33	0.40	1.10	5.30	3.60	3.60	13.30	1.90			
ÌgG	Pooled	Mean (OD)	2.60	2.59	2.60	2.65	2.67	2.65	2.69	2.45	2.43	2.55			
	+	SD	0.02	0.01	0.01	0.01	0.03	0.00	0.00	0.01	0.01	0.02	2.59	0.09	3.41
	serum	%CV	0.60	0.55	0.35	0.30	1.00	0.20	0.09	0.30	0.30	0.60			

Table S2: N-protein intra- and inter-assay variation. Assay variation was calculated for 10 plates assayed when testing saliva samples collected from household outbreaks.%CV was calculated using normalised OD values for Saliva Neg⁺ and Pos⁺⁺ QCs; raw OD values were taken for Pooled + serum⁺⁺⁺ %CVs.

* Top dilution for each standard considered: 1/10 for saliva IgA; 1/5 for saliva IgG; 1/50 for serum IgA; 1/1000 for serum IgG.

[†] Saliva Neg QC: used for monitoring assay performance and variation; composed of saliva from 2 individuals with no known history of COVID-19 infection.

^{††} Saliva Pos QC: used for monitoring assay performance and variation; composed of saliva from 3 individuals with PCR-confirmed COVID-19 infection.

^{†††}Pooled + serum: used for standardisation of measurements across assay plates; composed of sera from 3 individuals with PCR-confirmed COVID-19 infection.

Assay	Sample ID*	Mean/SD/ %CV	Plate 1	Plate 2	Plate 3	Plate 4	Plate 5	Plate 6	Plate 7	Plate 8	Plate 9	Plate 10	Inter-assay mean	Inter-assay SD	Inter-assay %CV
	Saliva Pos	Mean (norm.)	0.72	0.70	0.80	0.85	0.84	0.79	0.80	0.79	0.81	0.81			
	QC	SD	0.04	0.01	0.00	0.04	0.07	0.02	0.01	0.00	0.02	0.02	0.79	0.05	5.95
		%CV	2.37	0.31	0.00	1.80	3.80	0.80	0.50	0.01	1.10	0.80			
Spike	Saliva Neg	Mean (norm.)	0.04	0.03	0.04	0.05	0.04	0.05	0.05	0.05	0.05	0.05			
IgA	QC	SD	0.00	0.00	0.00	0.00	0.01	0.01	0.00	0.01	0.00	0.01	0.04	0.01	16.92
		%CV	4.42	5.24	3.11	3.30	11.10	4.10	0.60	5.50	0.90	5.00			
	Pooled +	Mean (OD)	2.60	2.59	2.59	2.44	2.47	2.53	2.50	2.48	2.43	2.50			
	serum	SD	0.02	0.01	0.00	0.01	0.19	0.02	0.02	0.05	0.00	0.00	2.51	0.06	2.47
		%CV	0.82	0.46	0.11	0.50	0.82	0.90	0.90	1.90	0.06	0.10			
	Saliva Pos	Mean (norm.)	0.69	0.58	0.74	0.77	/	0.77	0.75	0.76	0.72	0.76			
	QC	SD	0.02	0.02	0.01	0.01	/	0.01	0.07	0.10	0.03	0.00	0.73	0.06	8.62
		%CV	1.27	1.29	0.77	0.60	/	0.30	3.50	5.00	1.40	0.20			
Spike	Saliva Neg	Mean (norm.)	0.05	0.06	0.06	0.13	/	0.11	0.10	0.12	0.10	0.11			
IgG	QC	SD	0.00	0.04	0.00	0.00	/	0.01	0.01	0.02	0.01	0.01	0.09	0.03	30.64
		%CV	0.00	24.90	1.02	1.10	/	2.60	2.20	5.80	4.00	2.30			
	Pooled +	Mean (OD)	2.43	2.48	2.50	2.67	2.72	2.73	2.70	2.71	2.74	2.69			
	serum	SD	0.01	0.04	0.00	0.02	0.04	0.01	0.02	0.03	0.04	0.02	2.64	0.12	4.47
		%CV	0.26	1.45	0.08	0.80	1.30	0.30	0.80	1.10	1.50	0.60			

Table S3: Spike intra- and inter-assay variation. Assay variation was calculated for 10 plates assayed when testing saliva samples collected from household outbreaks. %CV was calculated using normalised OD values for Saliva Neg[†] and Pos^{††} QCs; raw OD values were taken for Pooled + serum^{†††} %CVs.

* Top dilution for each standard considered: 1/10 for saliva IgA; 1/5 for saliva IgG; 1/50 for serum IgA; 1/1000 for serum IgG.

[†] Saliva Neg QC: used for monitoring assay performance and variation; composed of saliva from 2 individuals with no known history of COVID-19 infection.

^{††} Saliva Pos QC: used for monitoring assay performance and variation; composed of saliva from 3 individuals with PCR-confirmed COVID-19 infections.

^{†††} Pooled + serum: used for standardisation of measurements across assay plates; composed of sera from 3 individuals with PCR-confirmed COVID-19 infections.

Table S4: Evaluation of assay performance in validation or combined sample sets.

Performance of Spike and N-protein IgA and IgG assays was evaluated on either the validation samples only or the threshold and validation set samples combined, using normalised OD as input values. AUC = Area under the curve. 95% CI = 95% confidence interval calculated for AUC using DeLong's method or computed with 10,000 stratified bootstrap replicates for sensitivity and specificity estimates. Sp. = specificity, Sens. = sensitivity.

			Validation	sample s	et		Combined	l sample so	et
Number of stested	samples	N pre-j	pandemic	N PCR	confirmed	N pro	e-pandemic	N PCR	confirmed
Spike IgA		1	.14		45		222		87
Spike IgG			99		42		196		83
N-protein Ig	gA		95		43		172		81
N-protein Ig	gG		95		43		172		80
Performanc	e	Α	UC	95	% CI		AUC	95	% CI
Spike IgA			7.9		7-93.1		89.9		5-93.2
Spike IgG			4.5		2-97.9		95.0		8-97.3
N-protein Ig	<u>z</u> A								
	-	7	2.6	64.	3-80.9		71.9	65.	7-78.1
N-protein Ig			9.4		2-94.7		84.6	79.	9-89.4
	Threshold method	Sp.	95% CI	Sens.	95% CI	Sp.	95% CI	Sens.	95% CI
Spike IgA	99th percentile	97.4	93.9-100	33.3	20-48.9	97.7	95.5-99.5	36.8	26.4-47.1
	98th percentile	97.4	93.9-100	33.3	20-48.9	97.3	95-99.1	37.9	27.6-48.3
	97th		86.8-						
	percentile	92.1	96.5	44.4	31.1-60	94.1	91-96.8	49.4	39.1-59.8
	Youden's index	78.1	70.2- 85.1	77.8	66.6-88.9	82	76.6-86.9	81.6	73.6-89.7
Spike IgG	99th percentile	100	100-100	40.5	26.2-54.8	99.5	98.5-100	44.6	33.7-55.4
	98th								
	percentile	100	100-100	47.6	33.3-61.9	99	97.4-100	50.6	39.8-61.4
	97th percentile	100	100-100	52.4	38.1-66.7	98.5	96.4-100	55.4	44.6-66.3
	Youden's	100	69.7-	52.1	50.1 00.7	70.5	20.1100	55.1	11.0 00.5
	index	77.8	85.9	90.5	81-97.6	81.6	76-86.7	94	88-98.8
N-protein	99th	00.0	06.0.100		0.7.0	00.0	07 1 100	0.47	0 (17
IgA	percentile 98th	98.9	96.8-100	2.3	0-7.0	98.8	97.1-100	2.47	0-6.17
	percentile	98.9	96.8-100	2.3	0-7.0	98.3	95.9-100	3.7	0-8.64
	97th								
	percentile	98.9	96.8-100	9.3	2.3-18.6	96.5	93.6-98.8	8.64	3.7-14.8
	Youden's index	58.9	49.5- 68.4	79.1	65.1-90.7	55.8	48.3-62.8	85.2	77.8-92.6
N-protein IgG	99th percentile	98.9	96.8-100	16.3	6.98-27.9	98.8	97.1-100	11.2	5-18.8
	98th								
	percentile 97th	98.9	96.8-100	25.6	14.0-39.5	98.3	95.9-100	17.5	10-26.2
	percentile	98.9	96.8-100	27.9	16.3-41.9	97.7	95.3-99.4	18.8	10-27.5
	Youden's	01.1	72.6-	70.1	(7 4 00 7	70 5	70 1 04 2	75	(5.92.9
	index	81.1	88.4	79.1	67.4-90.7	78.5	72.1-84.3	75	65-83.8

Table S5: Sensitivity analysis investigating the impact of including repeated measures from the same individual on assay performance (AUC). At each threshold (99th - 97th percentile and Youden's index) assay performance was evaluated for the full dataset (threshold and validation sample set combined with repeated measures included) and compared to the same data set with one observation per donor only using ROC curve analysis. AUC = Area under ROC curve

	Performan Dataset	nce on full			Number of tested in fu		Number of samples tested in dataset with one observation per donor		
Assay	AUC	95% CI	AUC	95% CI	Pre- pandemic	PCR confirmed	Pre- pandemic	PCR confirmed	
Spike IgA	89.9	86.5-93.2	91.3	87.6-95.3	222	87	108	79	
Spike IgG	95.0	92.8-97.3	94.4	91.0-97.7	196	83	87	75	
N-protein IgA	71.9	65.7-78.1	73.7	65-82.3	172	81	66	73	
N-protein IgG	84.6	79.9-89.4	84.4	78.1-90.7	172	80	66	72	

Table S6: Sensitivity analysis investigating the impact of including repeated measures from the same individual on assay performance (specificity and sensitivity). At each threshold (99th – 97th percentile and Youden's index) assay performance was evaluated for the full dataset (threshold and validation sample set combined with repeated measures included) and compared to the same data set with one observation per donor only. AUC = Area under curve.

only. AUC =				itivity estim dataset	ates		l on data	sitivity estim aset with one nor	
Assay*	Threshold method	Specificity	95% CI	Sensitivity	95% CI	Specificity	95% CI	Sensitivity	95% CI
Spike IgA	99th percentile	97.7	95.5- 99.5	36.8	26.4- 47.1	97.2	93.5- 100	36.7	26.6- 48.1
	98th percentile	97.3	95- 99.1	37.9	27.6- 48.3	97.2	93.5- 100	38	27.8- 49.4
	97th percentile	94.1	91- 96.8	49.4	39.1- 59.8	94.4	89.8- 98.1	49.4	38- 60.8
	Youden's index	82	76.6- 86.9	81.6	73.6- 89.7	86.1	79.6- 92.6	82.3	73.4- 89.9
Spike IgG	1	99.5	98.5- 100	44.6	33.7- 55.4	98.9	96.6- 100	44	33.3- 56
	98th percentile	99	97.4- 100	50.6	39.8- 61.4	97.7	94.3- 100	48	37.3- 60
	97th percentile	98.5	96.4- 100	55.4	44.6- 66.3	97.7	94.3- 100	52	41.3- 64
	Youden's index	81.6	76- 86.7	94	88- 98.8	81.6	73.6- 89.7	93.3	86.7- 98.7
N-protein IgA	99th percentile	98.8	97.1- 100	2.47	0-6.17	100	100- 100	2.74	0-6.85
	98th percentile	98.3	95.9- 100	3.7	0-8.64	98.5	95.5- 100	4.11	0-9.59
	97th percentile	96.5	93.6- 98.8	8.64	3.7- 14.8	95.5	89.4- 100	8.22	2.74- 15.1
	Youden's index	55.8	48.3- 62.8	85.2	77.8- 92.6	57.6	45.5- 69.7	84.9	76.7- 93.2
N-protein IgG	99th percentile	98.8	97.1- 100	11.2	5-18.8	100	100- 100	12.5	5.56- 20.8
	98th percentile	98.3	95.9- 100	17.5	10- 26.2	100	100- 100	19.4	11.1- 29.2
	97th percentile	97.7	95.3- 99.4	18.8	10- 27.5	98.5	95.5- 100	20.8	12.5- 30.6
	Youden's index	78.5	72.1- 84.3	75	65- 83.8	77.3	66.7- 86.4	75	63.9- 84.7

*Number of samples tested is given in Table S3

					Age	e group (y	ears)			
		0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+	Unk
N-protein	Number of samples	112	9	41	7	0	0	0	0	4
IgA	FPs	2	1	2	0	0	0	0	0	1
	Specificity	98.2%	88.9%	95.1%	100.0%	NA	NA	NA	NA	75.0%
N-protein	Number of samples	112	9	41	7	0	0	0	0	4
IgG	FPs	2	0	1	0	0	0	0	0	0
	Specificity	98.2%	100.0%	97.6%	100.0%	NA	NA	NA	NA	100.0%
	Number of samples	151	10	48	10	0	0	0	0	4
Spike IgA	FPs	0	0	4	0	0	0	0	0	1
	Specificity	100.0%	100.0%	91.7%	100.0%	NA	NA	NA	NA	75.0%
	Number of samples	128	9	45	11	0	0	0	0	4
Spike IgG	FPs	0	0	0	2	0	0	0	0	1
	Specificity	100.0%	100.0%	100.0%	81.8%	NA	NA	NA	NA	75.0%

Table S7: Specificity of assays and distribution of false positives by age on pre-pandemic samples. FP = false positive.

Table S8: Specificity of assays and distribution of false positives by sex on pre-pandemic samples. FP = false positive.

			Sex	
		Female	Male	Unknown
	Number of samples	58	111	4
N-protein IgA	FPs	1	4	1
	Specificity	98.3%	96.4%	75.0%
	Number of samples	58	111	4
N-protein IgG	FPs	1	2	0
	Specificity	98.3%	98.2%	100.0%
	Number of samples	80	139	4
Spike IgA	FPs	1	4	0
	Specificity	98.8%	97.1%	100.0%
	Number of samples	67	124	4
Spike IgG	FPs	1	1	1
	Specificity	98.5%	99.2%	75.0%

		Ti	me since symp	tom onset and s	aliva sample	
		Asymptomatic*	11-21 days	22-43 days	44-70 days	≥71 days
N-protein	Number of samples	8	5	23	24	21
IgA	FNs	8	4	20	22	20
	Sensitivity	0.0%	20.0%	13.0%	8.3%	4.8%
N-protein	Number of samples	8	5	23	23	21
IgG	FNs	8	4	18	16	20
	Sensitivity	0.0%	20.0%	21.7%	30.4%	4.8%
	Number of samples	9	5	24	26	23
Spike IgA	FNs	6	1	13	19	16
	Sensitivity	33.3%	80.0%	45.8%	26.9%	30.4%
	Number of samples	9	5	23	24	22
Spike IgG	FNs	8	2	9	11	11
	Sensitivity	11.1%	60.0%	60.9%	54.2%	50.0%

Table S9: Sensitivity of assays and distribution of false negatives by time since symptom onset and saliva collection on PCR confirmed cases. FN = false negative.

* Median [Min, Max] days post positive PCR test: 37 [15, 69] days

Table S10: Performance of AdaBoost classifiers to predict positive and negative individuals using samples in the combined threshold and validation sample set. Datasets used for model training and testing differed in size (92 - 150 individuals) depending upon the assay(s) included. See supplementary methods for full details on dataset construction.

Assay	Mean ROC AUC*	Standard deviation
N-protein IgA	0.539	0.105
RBD IgA	0.552	0.069
RBD IgA, RBD IgG	0.556	0.130
N-protein IgA, N-protein IgG	0.592	0.070
N-protein IgG	0.625	0.032
RBD IgG	0.650	0.178
Spike IgA	0.758	0.093
N-protein IgA, RBD IgA, Spike IgA	0.784	0.076
N-protein IgA, Spike IgA	0.786	0.066
Spike IgG	0.824	0.075
Spike IgA, Spike IgG	0.881	0.078
N-protein IgG, Spike IgG	0.886	0.044
N-protein IgG, RBD IgG, Spike IgG	0.942	0.070

^{*}Receiver operator characteristic (ROC) curve area under curve (AUC) score obtained by performing 5-fold cross-validation. Assays ordered by mean ROC AUC score.

Table S11: Detection of salivary antibody in household members given vaccination and infection status. The number and proportion of individuals with antibody above thresholds for positivity on at least one occasion measured by N-protein and spike IgA and IgG assays*

Assay	Unvaccinated PCR -ve (N=11)	Unvaccinated PCR +ve (N=16)	Vaccinated PCR -ve (N=20)	Vaccinated PCR +ve (N=20)
N-protein IgA	4 (36.4%)	3 (18.8%)	7 (35.0%)	11 (55.0%)
N-protein IgG	0 (0%)	2 (12.5%)	2 (10.0%)	4 (20.0%)
N-protein IgA or IgG	4 (36.4%)	4 (25.0%)	9 (45.0%)	12 (60.0%)
Spike IgA	4 (36.4%)	9 (56.3%)	9 (45.0%)	14 (70.0%)
Spike IgG	1 (9.1%)	11 (68.8%)	17 (85.0%)	20 (100%)
Spike IgA or IgG	4 (36.4%)	14 (87.5%)	18 (90.0%)	20 (100%)
* All unvaccinated indivi	duals were children.	Only 2 children (adol	lescents aged between	16-18 years) received

either 1 or 2 doses of vaccine, one of these vaccinated children became infected during the study.

STARD Appendix

Table S12: Study aims and objectives

Aims/Objectives	Description
Aim	Develop and evaluate salivary immunoassays suitable for large scale epidemiological and immunological SARS-CoV-2 studies and provide insights into mucosal immune responses to mild SARS-CoV-2 infection.
Objective 1	Develop standardised salivary immunoassays for detection of anti-SARS-CoV-2 IgA and IgG antibodies in saliva to spike protein, it's RBD and N- protein
Objective 2	Determine and evaluate salivary immunoassay diagnostic performance as screening assays for population salivo-prevalence surveys
Objective 3	Investigate how observed salivo-antibody responses correlate with serum antibody overtime to better understand immunological profiles
Objective 4	Field-test assays and characterise mucosal responses in households of adults and children with different levels of pre-existing immunity

Table S13: Test accuracy methods for index and reference tests

Method	Description
Index test	Salivary ELISA detecting IgA and IgG antibodies to
	SARS-CoV-2 spike protein, receptor binding domain,
	N-protein
Reference test	RT-PCR positive test performed on nose/throat swab.
	Selected as best available gold-standard for
	identifying current SARS-CoV-2 infection.
Test positivity index test cut-off	Test positivity cut-offs were established by setting
	thresholds on the pre-pandemic (known negative)
	population in the 'threshold set' to achieve ~98%
	specificity. See Table S1 for threshold values.
Test positivity reference test cut-off	RT-PCR tests were performed as part of national
	SARS-CoV-2 surveillance conducted by UK
	government laboratories.

Table S14: STARD Checklist

Section & Topic	No	Item	Reported on page
TITLE OR ABSTRACT			
	1	Identification as a study of diagnostic accuracy using at least one measure of accuracy	Abstract
		(such as sensitivity, specificity, predictive values, or AUC)	
ABSTRACT	_		
	2	Structured summary of study design, methods, results, and conclusions (for specific guidance, see STARD for Abstracts)	Abstract
INTRODUCTION			
	3	Scientific and clinical background, including the intended use and clinical role of the index test	Introduction
	4	Study objectives and hypotheses	Introduction, STARD Appendix Table S12
METHODS	_		
Study design	5	Whether data collection was planned before the index test and reference standard	Methods
		were performed (prospective study) or after (retrospective study)	
Participants	6	Eligibility criteria	Methods
	7	On what basis potentially eligible participants were identified	Methods
		(such as symptoms, results from previous tests, inclusion in registry)	
	8	Where and when potentially eligible participants were identified (setting,	Methods
		location and dates)	
	9	Whether participants formed a consecutive, random or convenience series	Methods
Test methods	10a	Index test, in sufficient detail to allow replication	Methods and STARD Appendix Table S13
	10b	Reference standard, in sufficient detail to allow replication	Methods and STARD Appendix Table S13
	11	Rationale for choosing the reference standard (if alternatives exist)	Methods and STARD Appendix Table S13
	12a	Definition of and rationale for test positivity cut-offs or result categories	Methods and
		of the index test, distinguishing pre-specified from exploratory	STARD Appendix Table S13
	12b	Definition of and rationale for test positivity cut-offs or result categories	Methods and
		of the reference standard, distinguishing pre-specified from exploratory	STARD Appendix Table S13
	13a	Whether clinical information and reference standard results were available to the performers/readers of the index test	Methods
	13b	Whether clinical information and index test results were available to the assessors of the reference standard	Methods
Analysis	14	Methods for estimating or comparing measures of diagnostic accuracy	Methods
	15	How indeterminate index test or reference standard results were handled	Methods
	16	How missing data on the index test and reference standard were handled	Methods
	17	Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory	Methods
	18	Intended sample size and how it was determined	Methods
RESULTS			
Participants	19	Flow of participants, using a diagram	Figure 1
	20	Baseline demographic and clinical characteristics of participants	Table 1

Table S14 continued			
Section & Topic	No	Item	Reported on page #
	21a	Distribution of severity of disease in those with the target condition	Table 1
	21b	Distribution of alternative diagnoses in those without the target condition	NA
	22	Time interval and any clinical interventions between index test and reference standard	Table 1
Test results	23	Cross tabulation of the index test results (or their distribution) by the results of the reference standard	Table 2
	24	Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals)	Table 2
	25	Any adverse events from performing the index test or the reference standard	NA
DISCUSSION			
	26	Study limitations, including sources of potential bias, statistical uncertainty, and generalisability	Discussion
	27	Implications for practice, including the intended use and clinical role of the index test	Discussion
OTHER INFORMATION			
	28	Registration number and name of registry	NA
	29	Where the full study protocol can be accessed	NA
	30	Sources of funding and other support; role of funders	Acknowledgements

Supplementary methods

Detection of SARS-CoV-2 infection by RT-qPCR on saliva

Table S15: Full sequences and final concentrations of primers and probes used in the SARS-CoV-2 N6/E/MS2 RT-qPCR multiplex assay. Probes were labelled with 6-Carboxyfluorescein (6-FAM) and Black Hole Quencher 1 (BHQ1) or Cyanine 5 (Cy5) and Black Hole Quencher 3 (BHQ3).

	Position*		Concentration used in RT-
Name		Sequence (5'-3')	qPCR
CoV2_N6_F Forward Primer	26269	GATGCTGCTCTTGCTTTGCT	200nM
CoV2_N6_R Reverse Primer	26381	CCTTGTTGTTGTTGGCCTTTAC	200nM
CoV2_N6_P Probe (FAM)	26332	6-FAM- CTGCTTGACAGATTGAACCAGCTTGAGAG- BHQ-1	100nM
E_Sarbeco_F1 Forward Primer	2163	ACAGGTACGTTAATAGTTAATAGCGT	200nM
E_Sarbeco_R2 Reverse Primer	2226	ATATTGCAGCAGTACGCACACA	200nM
E_Sarbeco_P1 Probe (FAM)	2183	6-FAM- ACACTAGCCATCCTTACTGCGCTTCG- BHQ-1	100nM
MS2 2155 F Forward primer	28919	ATGGGGCACAAGTTGCAG	50nM
MS2 2218 R Reverse primer	29001	GGGTAACGGTTGCTTGTTCA	50nM
MS2 2175 P Probe (CY5)	28940	Cy5-TGCAGCGCCTTACAAGAAGTTCGC-BHQ-3	50nM

* Position relative to SARS-CoV-2 isolate Wuhan-Hu-1 genome (accession MN908947.3) or MS2 phage genome (accession V00642.1).

Machine learning analysis evaluating performance when combining assays

To construct a dataset, we combined the samples in the threshold and validation sample set, using readings obtained from the lowest dilution of each assay (1 in 5 for N-protein, RBD and Spike IgG; 1 in 10 for N-protein, RBD and Spike IgA). The lowest dilution was selected as little difference was observed in the separation of positive and negative individuals across the different sample dilutions tested. The resulting dataset contained entries for 318 individuals. However, only 32 individuals had readings measured for all 6 assays. To ensure we had enough data available for 5-fold cross-validation (see below), we consequently decided to limit the assay combinations we tested to those containing either the same antigen (i.e., N-protein IgG and IgA; RBD IgG and IgA; and Spike IgG and IgA) or the same secondary antibody (i.e., N-protein, RBD and Spike IgG; and N-protein, RBD and Spike IgA). Given that, owing to poor performance, the RBD assays were not taken forwards for threshold setting nor to the field studies, we also tested combining just the N-protein and Spike antigens (N-protein and Spike IgG; and N-protein and Spike IgA). This meant that the sizes of the datasets we used for model training and testing were, depending upon the assay(s) included, in the range of 92 – 150 individuals.

We trained AdaBoost classifiers to predict positive and negative individuals using the datasets described above (i.e., 13 datasets in total -6 models were trained with the individual assays, and 7 models were trained with a combination of assays). Model performance was measured by calculating ROC AUC (area under the receiver operating characteristic curve) scores. Model training and testing were performed as part of a 5-fold crossvalidation loop. Accordingly, we obtained 5 ROC AUC scores for each assay combination, which are represented as dots in Fig 3(b), whilst the mean of these 5 values is plotted as a bar. The above analysis available data is as a Jupyter notebook at https://github.com/Bristol-UNCOVER/Saliva data ML analysis/blob/main/Saliva dataset analysis.ipynb.

The AdaBoost algorithm was imported into the notebook from the scikit-learn Python package.¹

¹ Pedregosa, F. *et al. Scikit-learn: Machine Learning in Python. Journal of Machine Learning Research* vol. 12 http://scikit-learn.sourceforge.net. (2011).